EyePoint Inc. (EYPT)
NASDAQ: EYPTIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
EYPT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $26.65M
- EPS (TTM)
- -$3.97
- Dividend yield
- None
- 52-week range
- 0.2277 – 19.11
- Day range
- 0.2277 – 0.265
- Volume / Avg
- 4.93M / 8.37M
- Beta
- —
- Shares outstanding
- 113.78M
52-week range
EYPT stock today
Shares of EyePoint (EYPT) finished lower on Nov 20 at $0.2342, a drop of 11.36% or $0.03 per share, versus the S&P 500's 3.70% decline. At this level, EYPT sits near the bottom of its 52-week range of $0.2277 to $19.11: 98.8% below the high, set on Dec 8, 2025 and 2.9% above the low. EYPT is down 98.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 98.3%.
EyePoint has posted a net loss over the last twelve months (EPS of -$3.97), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About EyePoint
Company profileEyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- CEO
- Dr. Jay S. Duker M.D.
- Headquarters
- Watertown, MA
- Employees
- 214
- Website
- eyepoint.bio
Financial highlights
Full financialsIn fiscal 2025, EyePoint generated $31.4 million in revenue, down 27.5% from fiscal 2024, its first annual decline since 2024. EyePoint reported a net loss of $232.0 million, compared with a loss of $130.9 million a year earlier. Operating margin was -776.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $31.37M | $43.27M | $46.02M | $41.40M | $36.94M |
| Growth | -27.50% | -5.97% | +11.14% | +12.09% | +7.27% |
| Net income | $-231.96M | $-130.87M | $-70.80M | $-102.25M | $-58.42M |
| EPS (diluted) | $-3.17 | $-2.32 | $-1.82 | $-2.74 | $-2.03 |
Analyst forecast
ForecastConsensus (13 analysts)
buy
Avg. price target
$25.91+10963.19%
- Strong buy 1
- Buy 6
- Hold 6
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-1.07 vs $-0.88
- Surprise
- -21.59%
EYPT news
All EYPT news- EYPT Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against EyePoint, Inc.PR Newswire
- EYPT Investors Have Opportunity to Lead EyePoint, Inc. Securities Fraud LawsuitPR Newswire
- EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate DevelopmentsNasdaq
- EyePoint Announces Participation at Upcoming Investor Conferences and Scientific MeetingsGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPTPR Newswire
- Weekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial WinNasdaqABBV, ABT, ACHV, ALVO
- Notable Monday Option Activity: EYPT, ABM, ORCLNasdaqEYPT, ABM, ORCL
EyePoint peers
Industrials sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PRPOPrecipio Inc. | 17.35 | -6.17% | $31.11M | vs EYPT |
| CIRCCircle8 Group Inc. | 0.1361 | -12.25% | $15.99M | vs EYPT |
| RPIDRapid Micro Biosystems Inc. Class A | 0.735 | -0.04% | $37.37M | vs EYPT |
| HBIOHarvard Bioscience Inc. | 8.66 | -0.23% | $39.60M | vs EYPT |
| BNGOBionano Genomics Inc. | 0.8222 | -7.11% | $11.50M | vs EYPT |
| ASTCAstrotech Corporation (DE) | 3.50 | -0.85% | $7.45M | vs EYPT |
| SEERSeer Inc. Class A | 1.36 | -1.81% | $75.91M | vs EYPT |
| QTRXQuanterix Corporation | 1.96 | -3.45% | $93.06M | vs EYPT |
Indexes, lists and sector
EyePoint stock FAQ
What is EyePoint's stock price today?
EYPT last traded at $0.2342 as of Nov 20, 4:00 PM EST, down 11.36% on the day. Prices are delayed at least 15 minutes.
Does EyePoint pay a dividend?
No. EyePoint does not currently pay a regular cash dividend.
Who is EyePoint's CEO?
Dr. Jay S. Duker M.D. is the chief executive officer of EyePoint Inc., which has about 214 employees.
Has EYPT ever split its stock?
Yes. The most recent EYPT stock split was a 1-for-10 split on Dec 9, 2020, one of 2 splits on record.
What is the EYPT 52-week high?
The 52-week high for EYPT is $19.11 and the 52-week low is $0.2277. The stock is currently 98.8% below its high.